Camilleri M, et al
Tirzepatide and heart failure: In a phase III trial, tirzepatide has demonstrated significant benefits in obese patients with heart failure, reducing the risk of major complications, including urgent heart failure visits, hospitalisations, increased diuretic treatment, and cardiovascular-related deaths, by 38% compared to placebo
Insurance coverage remains inconsistent for weight loss drugs, especially when prescribed primarily for obesity rather than diabetes
Inactive ingredients, formulation, route of administration in some cases, and regulatory pathway differ
We provide Miami patients with detailed education about maintaining the ozempic 2mg dose for weight loss while developing strategies for managing challenges that arise after learning where to get ozempic
Patients with previous reactions to other incretin-based therapies should discuss this with their healthcare provider, who may consider specialist advice before prescribing tirzepatide